| 14.7 1.79 (13.87%) | 06-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.56 |
1-year : | 22.85 |
| Resists | First : | 16.75 |
Second : | 19.56 |
| Pivot price | 13.57  |
|||
| Supports | First : | 13.74 |
Second : | 11.88 |
| MAs | MA(5) : | 13.13 |
MA(20) : | 13.84 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 17.9 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 16.75 | Low : | 11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GENB ] has closed below upper band by 24.2%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 15.06 - 15.12 | 15.12 - 15.19 |
| Low: | 12.71 - 12.76 | 12.76 - 12.82 |
| Close: | 14.59 - 14.68 | 14.68 - 14.8 |
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Mon, 01 Jun 2026
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - Sahm
Fri, 29 May 2026
GENB News | GENERATE BIOMEDICINES INC (NASDAQ:GENB) - ChartMill
Thu, 28 May 2026
Generate Biomedicines (GENB) Stock News - Stock Titan
Thu, 28 May 2026
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - PR Newswire
Thu, 21 May 2026
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
Thu, 14 May 2026
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 128 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 23.1 (%) |
| Held by Institutions | 71.7 (%) |
| Shares Short | 3,450 (K) |
| Shares Short P.Month | 2,080 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -12.24 |
| Profit Margin | 0 % |
| Operating Margin | -887.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -18.2 % |
| Gross Profit (p.s.) | -1.61 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -228 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.11 |
| PEG Ratio | 0 |
| Price to Book value | -1.21 |
| Price to Sales | 62.19 |
| Price to Cash Flow | -8.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|